China
Africa
Explore chapters and articles related to this topic
Treatment of Alzheimer’s disease
Published in Howard H. Feldman, Atlas of Alzheimer's Disease, 2007
Najeeb Qadi, Michele Assaly, Philip E. Lee
Cerebrolysin (FPF-1070) is a preparation of amino acids and peptides derived from purified porcine brain proteins. It is postulated to exhibit neurotropic activity similar to nerve growth factor,68 and may play a role in preserving cholinergic neurons.69 In a transgenic mouse model of AD, administration of Cerebrolysin reduced the size of amyloid plaques, possibly by regulating amyloid precursor protein maturation and decreasing transport to sites of Ab protein production.70 There has been some reported efficacy in randomized clinical trials performed in subjects with AD where the administration of intravenous administration of cerebrolysin demonstrated improvements on measures of cognition, global rating and activities of daily living.71–74 Though cerebrolysin appeared to be well tolerated, it is still at a stage of research interest requiring further study to see if there is sufficient efficacy and safety to reach regulatory approval.
Neuropharmacology for Older Adults
Published in José León-Carrión, Margaret J. Giannini, Behavioral Neurology in the Elderly, 2001
José León-Carrión, María Rosario Domínguez-Morales, Manuel Murga Sierra
Cerebrolysin is used in some countries in the treatment of vascular dementia, AD, acute stroke, traumatic brain injury, and cognitive and behavioral sequelae of neurosurgery. Although there is very little information concerning its peptide components and pharmacokinetics,16 this drug seems to show neurotropic and neuroprotective activity.
Protective effects of cerebrolysin against chemotherapy (carmustine) induced cognitive impairment in Albino mice
Published in Drug and Chemical Toxicology, 2022
Suraj Sharma, Khadga Raj, Shamsher Singh
Cerebrolysin (CBN) is a mixture of neurotrophic factors and active peptide fragments, useful to manage various neurological disorders due to antioxidant, anti-inflammatory, neuroregeneration, and neuroprotection properties (Gavrilova and Alvarez 2021). Moreover, cerebrolysin cross BBB permeability attenuates brain edema formation and improves neuronal damage in the cortex parts of the brain (Chen et al. 2013). The efficacy and safety of CBN have been demonstrated in recent clinical trials, including stroke, TBI (Masliah et al. 1999, Ziganshina et al. 2020). In addition, CBN exerts important pharmacological actions, including increase synaptic regeneration, decrease apoptosis, increase dendritic spine density and dendritic length (Abdel-Salam et al. 2018). Administration of cerebrolysin shows neuroprotective effects by reducing neuronal dysfunction and maintaining the structural integrity of neurons (Requejo et al. 2018). Although the mechanism of action of cerebrolysin has not been fully understood at a molecular level, it has been reported that it reduces the phosphorylation of amyloid precursor protein and amyloid-β peptide production via modulation of kinases GSK3b and CDK5 in the brain (Brainin 2018). Therefore, the present study has been designed to investigate the neuroprotective effects of cerebrolysin in carmustine-induced cognitive impairment mediated behavioral, biochemical, neuroinflammatory, and neurotransmitters alterations in experimental mice.
Cerebrolysin: a multi-target drug for recovery after stroke
Published in Expert Review of Neurotherapeutics, 2018
Neuroprotective effects were the focus of early studies with Cerebrolysin. Cerebrolysin is a neuropeptide preparation that mimics the action of neurotrophic factors. These regulate normal physiological functioning as well as survival and regeneration of nervous tissue after injury. One of these early stroke studies was a randomized, double-blind, placebo-controlled trial (RCT) with 146 patients, published by Ladurner et al. [2]. This trial showed beneficial effects of Cerebrolysin (50 ml/day for 21 days) on motor function recovery and in cognitive performance, especially within the first 14 days, but missed significant treatment effects at Day 90 (Figure 1). This was explained by the rather mild baseline impairment, particularly spontaneous recovery, which was reflected by a Barthel Index (BI) of ≥85 at Day 90 in 66.2% of placebo patients.
The effect of experimentally-induced diabetes on rat hippocampus and the potential neuroprotective effect of Cerebrolysin combined with insulin. A histological and immunohistochemical study
Published in Egyptian Journal of Basic and Applied Sciences, 2023
Doaa El-Adli, Salwa A. Gawish, Amany AbdElFattah Mohamed AbdElFattah, Mona Fm. Soliman
Insulin has been widely used for blood glucose control in people with DM. It exerts a neuroprotective effect by reducing glutamate, rather than by modifying glucose levels [9]. Also, it can inhibit neuronal necrosis and apoptosis as neurotrophic factors [10,11]. Cerebrolysin (Cbl) is a neurotropic drug that enhances brain health and cognitive performance. It includes many neurotrophic factors that participate in improving the integrity of the neuronal circuits. Cbl has a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, dementia and cognitive impairment [12].